Xlife Sciences AG
SIX:XLS

Watchlist Manager
Xlife Sciences AG Logo
Xlife Sciences AG
SIX:XLS
Watchlist
Price: 21.8 CHF 2.83% Market Closed
Market Cap: CHf125.8m

Xlife Sciences AG
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Xlife Sciences AG
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Xlife Sciences AG
SIX:XLS
Other
CHf0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Other
-CHf396k
CAGR 3-Years
-75%
CAGR 5-Years
1%
CAGR 10-Years
-11%
Siegfried Holding AG
SIX:SFZN
Other
-CHf6.3m
CAGR 3-Years
19%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Other
CHf488m
CAGR 3-Years
34%
CAGR 5-Years
9%
CAGR 10-Years
33%
Tecan Group AG
SIX:TECN
Other
-CHf2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Other
-CHf394k
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xlife Sciences AG
Glance View

Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.

XLS Intrinsic Value
7.05 CHF
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Xlife Sciences AG's Other?
Other
0 CHF

Based on the financial report for Dec 31, 2024, Xlife Sciences AG's Other amounts to 0 CHF.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett